Attenuation of inflammatory pain by puerarin in animal model of inflammation through inhibition of pro-inflammatory mediators

Publication date: August 2018
Source:International Immunopharmacology, Volume 61
Author(s): Muhammad Zia Ullah, Ashraf Ullah Khan, Ruqayya Afridi, Hina Rasheed, Sidra Khalid, Muhammad Naveed, Hussain Ali, Yeong Shik Kim, Salman Khan
In the current study, the puerarin was investigated for both acute Carrageenan and chronic CFA-induced inflammatory pain models. The Puerarin treatment significantly attenuated (P < 0.001) the mechanical hyperalgesia and mechanical allodynia in both Carrageenan and CFA-induced hyperalgesia. The Puerarin treatment also remarkably reduced (p < 0.001) the thermal hyperalgesic responses in both acute Carrageenan as well as chronic CFA-induced models. Furthermore, the Puerarin administration was also associated with significant inhibition of (p < 0.001) paw edema in both Carrageenan and CFA-induced models. The inflammatory mediators such as IL-1β, IL-6, TNF-α and vascular endothelial growth factor (VEGF) are significantly enhanced during inflammatory conditions, however, the Puerarin administration significantly altered (P < 0.001) the mRNA expression levels of these mediators. Additionally, the Puerarin treatment also significantly enhanced (P < 0.001) the mRNA expressions levels of the anti-oxidant enzymes such as Nrf2, HO-1 and SOD2. The Puerarin treatment is associated with significant (P < 0.001) inhibition of the acetic acid-induced Evans blue vascular permeability. Moreover, the concentration of Puerarin in various tissues was analyzed using High-performance liquid chromatography (HPLC) and the results showed that the Puerarin was significantly distributed towards the peripheral tissues such as liver and kidney and less distributed towards the brain.

Graphical abstract

https://ift.tt/2HRgWmc